Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary

Ardelyx, Inc. (Nasdaq: ARDX) announced its participation in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022, at 10:00 a.m. ET in New York City. The management will engage in a fireside discussion, highlighting the company’s mission to innovate first-in-class medicines for unmet medical needs. Ardelyx's first product, IBSRELA® (tenapanor), is already available in the U.S. and Canada. The company is also advancing its product candidate, XPHOZAH® (tenapanor), for treating serum phosphorus in CKD patients on dialysis, following successful Phase 3 trials.

WALTHAM, Mass., Nov. 22, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside discussion at the 34^th Annual Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 10:00 a.m. ET in New York City.  

To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 30 days following the conference.

About Ardelyx, Inc.

Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories. For more information, please visit https://ardelyx.com/ and connect with us on Twitter @Ardelyx, LinkedIn and Facebook.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-34th-annual-piper-sandler-healthcare-conference-301684752.html

SOURCE Ardelyx

FAQ

What event will Ardelyx participate in on December 1, 2022?

Ardelyx will participate in the 34th Annual Piper Sandler Healthcare Conference.

What time is Ardelyx's presentation at the Piper Sandler Conference?

Ardelyx's presentation is scheduled for 10:00 a.m. ET.

Where is the Piper Sandler Healthcare Conference being held?

The conference is being held in New York City.

How can I access Ardelyx's presentation webcast?

The live webcast can be accessed on Ardelyx's Events & Presentations page within the Investor section of their website.

What products is Ardelyx developing?

Ardelyx is developing XPHOZAH® (tenapanor) for CKD patients and RDX013 for treating elevated serum potassium.